EyeGate Pharmaceuticals has filed a supplement to its investigational device exemption for punctate epitheliopathy using its Ocular Bandage Gel, according to a press release.
“The filing of this IDE supplement represents the next step for our OBG platform and shows EyeGate’s continued progress,” Stephen From, EyeGate president and CEO, said in the release. “We are hopeful that we will receive a positive response to this IDE supplement and will be able to move into the clinic in the second half of 2018.”
The IDE for the Ocular Bandage Gel was (Read more...)
Uncategorized